Features of the course of diabetes mellitus in IgG4-associated disease
https://doi.org/10.14341/DM13054
Abstract
IgG4-related disease (IgG4-RD) is characterized by the appearance of tumor-like foci in one or more organs, occurring synchronously or metachronously, due to fibro-inflammatory changes with hypersecretion of immunoglobulin G subclass 4 (IgG4) in tissues and/or blood serum. Diabetes mellitus (DM) develops among 43-68% of patients with IgG4-related pancreatitis. Diabetes against the background of IgG4-RD can be caused both by damage to the endocrine part of the pancreas and the use of glucocorticosteroids, but its course is moderate, with a rare need for insulin therapy. In both cases, the use of genetically engineered biological therapy with rituximab may be accompanied by an improvement in carbohydrate metabolism. This article describes the course of diabetes and the need for hypoglycemic therapy for 1.5 years in a patient treated with IgG4-RD.
About the Authors
T. S. Panevin
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Taras S. Panevin - PhD, MD.
34A Kashirskoye Highway, 115522 Moscow
Competing Interests:
None
A. V. Torgashina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Anna V. Torgashina - PhD, MD.
Moscow
Competing Interests:
None
A. A. Movsesyan
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Anastasia A. Movsesyan.
Moscow
Competing Interests:
None
References
1. Sokol EV. IgG4-related disease: what do we know after 20 years. Therapeutic Archive. 2020;92(5):104-109. (In Russ.). doi: https://doi.org/10.26442/00403660.2020.05.000632
2. Yukina MY, Troshina EA, Platonova NM, Nuralieva NF. The autoimmune IgG4 -associated endocrine pathology. Obesity and metabolism. 2017;14(3):43-47. (In Russ.). doi: https://doi.org/10.14341/OMET2017343-47
3. Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 I. Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol. 2014;49(4):567-588. doi: https://doi.org/10.1007/s00535-014-0942-2
4. Löhr J, Beuers U, Vujasinovic M, et al. European Guideline on IgG4‐related digestive disease — UEG and SGF evidence‐based recommendations. United Eur Gastroenterol J. 2020;8(6):637-666. doi: https://doi.org/10.1177/2050640620934911
5. Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. BMJ. 2020;369:m1067. doi: https://doi.org/10.1136/bmj.m1067
6. Yamada T, Hiraoka E, Miyazaki T, et al. Diabetes as first manifestation of autoimmune pancreatitis. Am J Med Sci. 2017;353(5):498-499. doi: https://doi.org/10.1016/j.amjms.2016.08.022
7. Okazaki K, Uchida K, Matsushita M, Takaoka M. Autoimmune Pancreatitis. Intern Med. 2005;44(12):1215-1223. doi: https://doi.org/10.2169/internalmedicine.44.1215
8. Ghazale A, Chari ST, Smyrk TC, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol. 2007;102(8):1646-1653. doi: https://doi.org/10.1111/j.1572-0241.2007.01264.x
9. Ragimov MR, Derevyanko O, Ibragimova LI, et al. Exocrine pancreatic autoantibodies levels higher in long-standing type 1 diabetes. Diabetes Technology & Therapeutics. Feb 2020. Volume: 22 Issue S1: February 18, 2020. Abstract #705. doi: https://doi.org/10.1089/dia.2020.2525.abstracts
10. Dedov II, Shestakova MV, Vikulova OK, et al. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018;21(3):144-159. (In Russ.). doi: https://doi.org/10.14341/DM9686
11. Tanaka S, Kobayashi T, Nakanishi K, et al. Evidence of primary beta-cell destruction by T-cells and beta-cell differentiation from pancreatic ductal cells in diabetes associated with active autoimmune chronic pancreatitis. Diabetes Care. 2001;24(9):1661-1667. doi: https://doi.org/10.2337/diacare.24.9.1661
12. Miyazawa M, Takatori H, Shimakami T, et al. Prognosis of type 1 autoimmune pancreatitis after corticosteroid therapy-induced remission in terms of relapse and diabetes mellitus. PLoS One. 2017;12(11):e0188549. doi: https://doi.org/10.1371/journal.pone.0188549
13. Kharlashina EA, Kononenko IV, Smirnova OM, Mayorov AY. Diabetes mellitus due to biliary recurrent pancreatitis. Case report. Diabetes Mellitus, 2011;14(2):121-125. (In Russ.). doi: https://doi.org/10.14341/2072-0351-5648
14. Noguchi K, Nakai Y, Mizuno S, et al. Insulin secretion improvement during steroid therapy for autoimmune pancreatitis according to the onset of diabetes mellitus. J Gastroenterol. 2020;55(2):198-204. doi: https://doi.org/10.1007/s00535-019-01615-4
15. Nishimori I, Tamakoshi A, Kawa S, et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis. Pancreas. 2006;32(3):244-248. doi: https://doi.org/10.1097/01.mpa.0000202950.02988.07
16. Masuda A, Shiomi H, Matsuda T, et al. The relationship between pancreatic atrophy after steroid therapy and diabetes mellitus in patients with autoimmune pancreatitis. Pancreatology. 2014;14(5):361-365. doi: https://doi.org/10.1016/j.pan.2014.07.005
Supplementary files
Review
For citations:
Panevin T.S., Torgashina A.V., Movsesyan A.A. Features of the course of diabetes mellitus in IgG4-associated disease. Diabetes mellitus. 2023;26(4):370-374. (In Russ.) https://doi.org/10.14341/DM13054
Views:
700
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
